APA (7th ed.) Citation

CH, L., PW, L., CJ, T., YC, S., TC, C., SF, Y., & BS, K. (2026). Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study. Journal of the Formosan Medical Association = Taiwan yi zhi. https://doi.org/10.1016/j.jfma.2026.03.120

Chicago Style (17th ed.) Citation

CH, Lin, Liao PW, Teng CJ, Su YC, Chen TC, Yang SF, and Ko BS. "Daratumumab, Lenalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma: A Real-world Propensity Score-matched Study." Journal of the Formosan Medical Association = Taiwan Yi Zhi 2026. https://doi.org/10.1016/j.jfma.2026.03.120.

MLA (9th ed.) Citation

CH, Lin, et al. "Daratumumab, Lenalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma: A Real-world Propensity Score-matched Study." Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2026, https://doi.org/10.1016/j.jfma.2026.03.120.